EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Specific FAHFAs predict worsening glucose tolerance in non-diabetic relatives of people with Type 2 diabetes

Ismail Syed, Ken Sluis, Pratik Aryal, Zachary Solomon, Rucha Patel, Srihari Konduri, Dionicio Siegel, Ulf Smith, Barbara B Kahn

Journal of Lipid Research · 2025

DOI: 10.1016/j.jlr.2025.100819 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Lipid Research, 2025. Verfasst von Ismail Syed und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, …. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucose Intolerance, Palmitic Acid, Fatty Acids. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, JPB Foundation, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is a growing need for early biomarkers for Type 2 diabetes (T2D). Fatty-Acid-Hydroxy-Fatty-Acids (FAHFAs) are bioactive lipids with >580 regioisomers in human tissues. FAHFAs such as Palmitic Acid Hydroxy Stearic Acids (PAHSAs) are anti-diabetic and anti-inflammatory. PAHSA concentrations in human serum and adipose tissue strongly correlate with insulin sensitivity. Since PAHSAs and palmitic acid hydroxy oleic acids (PAHOAs) are among the most abundant FAHFAs in human serum, we investigated whether they predict worsening glucose tolerance in first-degree relatives of people with T2D. All participants had normal glucose tolerance (NGT) at baseline; 27 remained NGT (NGT-NGT) and 21 developed impaired glucose tolerance (NGT-IGT). In NGT-NGT, total PAHSA and PAHSA regioisomer concentrations were unchanged from baseline to follow-up, while in NGT-IGT participants, most PAHSA regioisomers decreased. The initial total PAHSAs, 5-PAHSA, and 9-PAHSA, and changes in these correlated inversely with worsening glucose tolerance. Low total PAHSA concentrations at baseline and the decrease in total PAHSAs, 5-PAHSAs, and 9-PAHSAs over time predicted IGT independent of initial BMI or %body fat, change in BMI or in %body fat, initial fasting glucose, fasting insulin, or triglyceride/HDL ratio. In contrast, baseline and follow-up total PAHOA and PAHOA regioisomer levels were higher in NGT-IGT than NGT-NGT, and some PAHOA regioisomers increased during follow-up in NGT-IGT. Higher initial total PAHOAs predicted IGT independent of the same clinical variables. Thus, lower serum PAHSAs and higher PAHOAs predict worsening glucose tolerance/IGT independent of BMI, %body fat, or change in these parameters, even in lean, relatively young people.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucose IntolerancePalmitic AcidFatty AcidsHumansFemaleMaleMiddle AgedAdultAgedGlucose Tolerance TestFamilyBiomarkers

Stichwörter der Autor:innen

BMIHOMAType 2 diabetesanti-diabetic and anti-inflammatory lipidsfatty acid hydroxy fatty acidsimpaired glucose tolerancelipid biomarkerspalmitic acid hydroxy oleic acidspalmitic acid hydroxy stearic acids

Substanzen

Palmitic AcidFatty AcidsBiomarkers

Autor:innen und Institutionen

  • Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA. Electronic address: isyed@bidmc.harvard.edu.
  • Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
  • Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.
  • The Lundberg Laboratory for Diabetes Research, Departments of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
  • Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA. Electronic address: bkahn@bidmc.harvard.edu.

Förderung

  • NIDDK NIH HHS
  • JPB Foundation
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Syed, I., Sluis, K., Aryal, P., Solomon, Z., Patel, R., Konduri, S., Siegel, D., Smith, U., & Kahn, B. B. (2025). Specific FAHFAs predict worsening glucose tolerance in non-diabetic relatives of people with Type 2 diabetes. Journal of Lipid Research. https://doi.org/10.1016/j.jlr.2025.100819

Vancouver

Syed I, Sluis K, Aryal P, Solomon Z, Patel R, Konduri S, et al. Specific FAHFAs predict worsening glucose tolerance in non-diabetic relatives of people with Type 2 diabetes. Journal of Lipid Research. 2025. doi:10.1016/j.jlr.2025.100819

BibTeX
@article{Syed2025,
  author = {Syed, Ismail and Sluis, Ken and Aryal, Pratik and Solomon, Zachary and Patel, Rucha and Konduri, Srihari and Siegel, Dionicio and Smith, Ulf and Kahn, Barbara B},
  title = {Specific FAHFAs predict worsening glucose tolerance in non-diabetic relatives of people with Type 2 diabetes},
  journal = {Journal of Lipid Research},
  year = {2025},
  doi = {10.1016/j.jlr.2025.100819}
}
Kostenlos starten →